Data News Insights | KlickAnalytics

Regeneron Pharmaceuticals, Inc. (REGN)

REGN is trading UP for the last 1 days, and it at trading at $798.87 with volume of 237,954 and a one day change of $4.68 (0.59%). Regeneron Pharmaceuticals, Inc. has a 52-week low of 538.23 and a 52-week high of $844.90. The business's 50-day moving average price is $715.96 and its 200 day moving average price is $726.81. The firm has a market cap of $82 million, a P/E ratio of 18.96, and a beta of 0.39.

Top news headlines for REGN

This timeline-focused notice highlights allegations that Regeneron's Phase III Fianlimab-Libtayo disclosures evolved from delayed event accrual to a protocol amendment and then a failed primary endpoint, with REGN investors allegedly absorbing substantial share-price losses This timeline-focused notice highlights allegations that Regeneron's Phase III Fianlimab-Libtayo disclosures evolved from delayed event accrual to a protocol amendment and then a failed primary endpoint, with REGN investors allegedly absorbing substantial share-price losses

LOS ANGELES, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc. (“Regeneron” or “the Company”) (NASDAQ: REGN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of REGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.

SAN FRANCISCO, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to treat patients with melanoma. The news that the trial failed drove the price of Regeneron shares sharply lower and, along with the severe market reaction ($11 billion market cap wipeout), triggered the lawsuit which seeks to represent investors who purchased or otherwise acquired shares of Regeneron common stock between August 1, 2025 and May 15, 2026.

Corient Private Wealth LP acquired a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 14,670 shares of the biopharmaceutical company's stock, valued at approximately $9,148,000. Other large investors also recently

Corient Private Wealth LP cut its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 23.9% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 13,758 shares of the biopharmaceutical company's stock after selling 4,315 shares during the quarter.

For more information on REGN:

Gilead Sciences, Inc. (GILD)

GILD is trading UP for the last 1 days, and it at trading at $146.45 with volume of 2,055,750 and a one day change of $0.77 (0.53%). Gilead Sciences, Inc. has a 52-week low of 106.44 and a 52-week high of $155.38. The business's 50-day moving average price is $134.10 and its 200 day moving average price is $132.68. The firm has a market cap of $181 million, a P/E ratio of -56.03, and a beta of 0.33.

For more information on GILD:

IDEXX Laboratories, Inc. (IDXX)

IDXX is trading UP for the last 2 days, and it at trading at $557.82 with volume of 263,851 and a one day change of $2.83 (0.51%). IDEXX Laboratories, Inc. has a 52-week low of 518.55 and a 52-week high of $769.98. The business's 50-day moving average price is $559.10 and its 200 day moving average price is $611.05. The firm has a market cap of $44 million, a P/E ratio of 38.97, and a beta of 1.69.

Top news headlines for IDXX

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (Nasdaq: IDXX), a global leader in pet healthcare innovation, today announced that Mike Erickson, President and Chief Executive Officer, and Andrew Emerson, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026, from 10:45 am – 11:20 am (ET). A live audio webcast of the fireside chat will be available through.

[url="]IDEXX Laboratories, Inc.[/url] (Nasdaq: IDXX), a global leader in pet healthcare innovation, today announced that Mike Erickson, President and Chief Exec

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

For more information on IDXX:

Vertex Pharmaceuticals Incorporated (VRTX)

VRTX is trading UP for the last 1 days, and it at trading at $544.14 with volume of 297,500 and a one day change of $2.45 (0.45%). Vertex Pharmaceuticals Incorporated has a 52-week low of 374.17 and a 52-week high of $555.69. The business's 50-day moving average price is $500.55 and its 200 day moving average price is $463.23. The firm has a market cap of $137 million, a P/E ratio of 31.28, and a beta of 0.32.

For more information on VRTX: